Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
Social Determinants of Health and Prevention of Cardiovascular Disease
Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
High Discontinuation Rates of GLP-1 RA-Based Drugs Linked to Weight Loss Far Below Phase 3 Clinical Trials
High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
George Medicines Announces FDA Approval of Polypill for Treatment of Hypertension in Adults
The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Regeneron Phase 2b Study Shows Antibodies Help Preserve Lean Mass During Weight Loss with Semaglutide
Interim results from COURAGE trial suggest combining semaglutide with muscle-preserving antibodies significantly enhances fat loss while preserving lean mass in obesity treatment.
High-Quality Macronutrients Key to Cardiovascular Risk Reduction, Large Cohort Study Finds
Research reveals that the quality of foods in low-carb and low-fat diets significantly impacts heart health, emphasizing whole, plant-based options.
High Discontinuation Rates of GLP-1 RA-Based Drugs Linked to Weight Loss Far Below Phase 3 Clinical Trials
High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
George Medicines Announces FDA Approval of Polypill for Treatment of Hypertension in Adults
The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Regeneron Phase 2b Study Shows Antibodies Help Preserve Lean Mass During Weight Loss with Semaglutide
Interim results from COURAGE trial suggest combining semaglutide with muscle-preserving antibodies significantly enhances fat loss while preserving lean mass in obesity treatment.
High-Quality Macronutrients Key to Cardiovascular Risk Reduction, Large Cohort Study Finds
Research reveals that the quality of foods in low-carb and low-fat diets significantly impacts heart health, emphasizing whole, plant-based options.